Reuters logo
BRIEF-Galapagos says GLPG1690 halts disease progression in IPF patients in mid-stage trial
2017年8月9日 / 晚上8点08分 / 4 个月前

BRIEF-Galapagos says GLPG1690 halts disease progression in IPF patients in mid-stage trial

Aug 9 (Reuters) - Galapagos Nv

* GLPG1690 halts disease progression in IPF patients in Flora phase 2A trial

* Galapagos NV says GLPG1690 was generally well tolerated

* Galapagos NV - ‍GLPG1690 expected to progress to late stage trial​

* Galapagos NV -‍ rates of discontinuation due to adverse events, as well as serious adverse event rates, were similar between patients on GLPG1690, placebo​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below